Vital Therapies competitors

David 'Dave' Johnson works at Convatec Healthcare B Sarl and a Board Member at Orthopaedic Synergy Inc, Chairman and CEO of Enveric Biosciences at Enveric Biosciences Inc, and Chairman at AcquaMed Technologies and is based in Philadelphia, Pennsylvania. He has worked as Board Member at ALLIQUA BIOMEDICAL, INC.; President at Bristol-Myers Squibb; and Member of the Board of Directors; Chairman of the Compensation Committee at OMNI Orthopaedics. David works or has worked at Thermo Fisher Scientific and BAXTER INTERNATIONAL INC and works or has worked as FELLOW at The Wharton School, Chair:Global Wound Sector Team at AdvaMed, and Chief Executive Officer at Convatec Healthcare B Sarl. He studied at INSEAD between 2000 and 2000, The Wharton School between 2001 and 2005, and University of Alberta.

Jean-Jacques Bienaime is a Board Member at Biotechnology Innovation Organization - BIO, Director at INCYTE CORP, and Chairman/CEO at BioMarin Pharmaceutical Inc and is based in Novato, California. He has experience at Rhône Poulenc Rorer and has worked as President/CEO at GENENCOR INTERNATIONAL INC, Board Member at NeurogesX Inc, and Marketing Director at Genentech. Jean attended ESCP Europe, Ecole Superieure de Commerce de Paris between 1974 and 1976, and University of Pennsylvania.

Michael Castagna is a Board Member at MANNKIND CORP and Chief Executive Officer at MANNKIND CORP and is based in Westlake Village, California. He has worked as Vice President & Head, Biopharmaceuticals North America at Sandoz; Director, Endocrinology Marketing at Healthcare Business of Merck; and VP/Global Head:Commercial at Amgen. Michael attended Massachusetts College of Pharmacy and Health Sciences between 2012 and 2014, The Wharton School between 2003 and 2005, and Philadelphia College of Pharmacy & Science.

Speck Loe works at Medimmune and a Ceo at Medimmune and is based in Granite Falls, Washington.

Jeffrey Dunn has over thirty years of executive experience, including serving as the CEO of six companies. His medical device experience includes sacroiliac surgery, ankle replacement, and small bone extremity fusion. Jeffrey Dunn has taken one company public, sold all the others to larger public companies, served on numerous boards of directors and is an advisor to other CEOs. Prior to SI-BONE, Inc. Jeffrey Dunn was CEO of INBONE Technologies, which he built into a leading ankle replacement and small bone fusion medical device company. Jeffrey Dunn led the sale of INBONE to Wright Medical in April, 2008. Jeffrey Dunn was the CEO of Active Decisions. Brought in to effect a turnaround, he closed down a major product line and redirected the technology to the ''software as a service'' model. Active Decisions was bought by Knova Software, a public company that was subsequently sold to Consona, a private equity firm. Previously, Jeffrey Dunn was the CEO of Velogic, an Internet performance testing software company. At Velogic, Jeffrey Dunn reinvented and expanded the product line, restructured the management team and created industry partnerships, one of which ultimately led to the acquisition of the company by Keynote Systems. Jeffrey Dunn was also the CEO of EnterpriseLink, a provider of enterprise Internet enablement software. Jeffrey Dunn was recruited to lead a turnaround by the investors. Jeffrey Dunn reinvigorated the company and successfully sold the company for a substantial gain in less than one year. Jeffrey Dunn was also the CEO of AccelGraphics, a 3D graphics systems supplier. Jeffrey Dunn created AccelGraphics by orchestrating a spin out from Kubota Graphics. He built the company into a rapidly growing enterprise (the 8th fastest growing Silicon Valley public company in 1997). The company was subsequently sold to Evans and Sutherland. Jeffrey Dunn has also held executive positions with Evans and Sutherland, Cygnet Systems, Avnet and Xerox. Jeffrey Dunn holds a BA degree from Colgate University and earned an MBA from Babson College.

Christopher Bossi is a President & CEO at In Range Systems, Inc.

Glendon French is a President/CEO at Pulmonx and Board Member at Pulmonx. He has worked as Board Member at Cardiac Pathways Corp, Board Member at Asthmatx Inc, and Chief Executive Officer/Director at ApniCure Inc. Glendon works or has worked as TRUSTEE at The Oliver Fund. He attended DARTMOUTH COLLEGE and The Wharton School.